<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79251">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073747</url>
  </required_header>
  <id_info>
    <org_study_id>EM 2014.01</org_study_id>
    <nct_id>NCT02073747</nct_id>
  </id_info>
  <brief_title>The Various Effects of Gaseous Albuterol on Serum Lactate</brief_title>
  <official_title>The Various Effects of Gaseous Albuterol on Serum Lactate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center of Southern Nevada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center of Southern Nevada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Empirical data from physician observation indicates an increase in serum lactate in acute
      asthmatic patients being treated with inhaled albuterol therapy.

      It is not clear if this increased serum lactate is in response to a physiological response
      to the asthmatic process or from the albuterol treatment.

      This study is designed to determine if administration of inhaled albuterol increases serum
      lactate in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 30 healthy volunteers will be randomized to Albuterol or placebo. We powered
      our study to detect a difference of 0.5 mmol/L, but hypothesize that the difference will be
      greater than 1.0 mmol/L.

      All volunteer subjects will sign a written consent, approved by the Institutional Review
      Board. The intended pool of volunteers will be from residents, attendings, and medical
      students in the hospital. The consent form will clearly specify that their participation in
      the study will not impact their academic status or employment.

      The subjects randomized to the Albuterol arm will receive a one hour 10 mg continuous
      Albuterol nebulizer treatment. Those randomized to placebo will receive a one-hour saline
      nebulizer treatment. The chief pharmacist for the study will randomly assign a number
      between one and thirty to fifteen Albuterol treatments and fifteen placebo treatments.

      Subjects will be monitored with cardiac monitor and serum lactate levels will be drawn every
      15 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with a change from baseline serum lactate following a one hour albuterol nebulizer treatment.</measure>
    <time_frame>Change in serum lactate from baseline at 15 min, 30 min, 45 min and 1 hour</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Normal Saline Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group will be administered a one hour normal saline inhaled treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albuterol Trial Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trial group to be administered one hour treatment of ten milligrams of inhaled albuterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>One hour inhaled normal saline</description>
    <arm_group_label>Normal Saline Control Group</arm_group_label>
    <other_name>NS</other_name>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
    <description>One hour inhaled ten milligrams of albuterol</description>
    <arm_group_label>Albuterol Trial Group</arm_group_label>
    <other_name>Ventilin</other_name>
    <other_name>Proventil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

        Exclusion Criteria:

          -  Pregnant

          -  Prisoner

          -  beta agonist allergy

          -  hypokalemia

          -  taking furosemide, insulin, thiazide diuretics, metformin or acetazolamide

          -  coronary artery disease

          -  hyperthyroidism

          -  abnormal heart rhythm

          -  baseline serum lactate level &gt;2.2 mmol/L

          -  baseline heart rate &gt; 120
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua R Parker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Medicine Residency Faculty</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Appel D, Rubenstein R, Schrager K, Williams MH Jr. Lactic acidosis in severe asthma. Am J Med. 1983 Oct;75(4):580-4.</citation>
    <PMID>6414303</PMID>
  </reference>
  <reference>
    <citation>Roncoroni AJ, Adrougué HJ, De Obrutsky CW, Marchisio ML, Herrera MR. Metabolic acidosis in status asthmaticus. Respiration. 1976;33(2):85-94.</citation>
    <PMID>778959</PMID>
  </reference>
  <reference>
    <citation>Manthous CA. Lactic acidosis in status asthmaticus : three cases and review of the literature. Chest. 2001 May;119(5):1599-602. Review.</citation>
    <PMID>11348975</PMID>
  </reference>
  <reference>
    <citation>Maury E, Ioos V, Lepecq B, Guidet B, Offenstadt G. A paradoxical effect of bronchodilators. Chest. 1997 Jun;111(6):1766-7. Review.</citation>
    <PMID>9187208</PMID>
  </reference>
  <reference>
    <citation>Chaulier K, Chalumeau S, Ber CE, Bret M, Rimmelé T. [Metabolic acidosis in a context of acute severe asthma]. Ann Fr Anesth Reanim. 2007 Apr;26(4):352-5. Epub 2007 Mar 8. French.</citation>
    <PMID>17349773</PMID>
  </reference>
  <reference>
    <citation>Rodrigo GJ, Rodrigo C. Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma. Emerg Med J. 2005 Jun;22(6):404-8.</citation>
    <PMID>15911945</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>October 26, 2016</lastchanged_date>
  <firstreceived_date>February 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center of Southern Nevada</investigator_affiliation>
    <investigator_full_name>Joseph Anthony Zitek</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Albuterol</keyword>
  <keyword>Serum Lactate</keyword>
  <keyword>Lactic Acidosis</keyword>
  <keyword>Asthma</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
